Skip to content
OpenCapital
Get started

Vir Biotechnology, Inc. VIR Total cash, cash equivalents and investments

Other financials

Income statement

See full
Revenue-$29.0K-101%
Gross profit$1.2M-60.2%
Operating income-$132.3M+5.2%
Net income-$125.7M-3.9%
EPS (diluted)-$0.85+3.4%

Balance sheet

See full
Cash & equivalents$283.0M-23.1%
Total debt$95.6M-0.5%
Total equity$812.8M-22.1%
Total assets$1.0B-21.6%

Cash flow

See full
Operating cash flow-$132.4M-69.5%
CapEx$390.0K-76.1%
Free cash flow-$132.8M-66.5%

Valuation

See full
Market cap$1.68B+61.1%
Enterprise value$1.49B+102%
P/S25.6×-24.3×

Profitability

See full
Gross margin96.1%-2.7pp
Operating margin-720.8%-313pp
Net margin-676%-291pp
FCF margin-686.5%-273pp

Returns & leverage

See full
Return on equity-47.7%+3.6pp
Debt / equity0.1×0.0×
Current ratio7.1×+0.3×

Where this comes from

Reported directly by Vir Biotechnology, Inc. in its filing.

Tagged under the XBRL concept vir:CashCashEquivalentsAndInvestments.

The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vir Biotechnology, Inc.'s total cash, cash equivalents and investments.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vir Biotechnology, Inc.'s total cash, cash equivalents and investments?
Vir Biotechnology, Inc. (VIR) reported total cash, cash equivalents and investments of $809.27M in Q1 2026.
How has Vir Biotechnology, Inc.'s total cash, cash equivalents and investments changed year-over-year?
Vir Biotechnology, Inc.'s total cash, cash equivalents and investments decreased by 20.6% year-over-year, from $1.02B to $809.27M.